Robert Janssen - Aug 5, 2022 Form 4 Insider Report for DYNAVAX TECHNOLOGIES CORP (DVAX)

Role
Senior Vice President
Signature
/s/ Robert Janssen
Stock symbol
DVAX
Transactions as of
Aug 5, 2022
Transactions value $
-$35,662
Form type
4
Date filed
8/9/2022, 07:54 PM
Previous filing
Mar 4, 2022
Next filing
Aug 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DVAX Common Stock Options Exercise $9.42K +900 +3.64% $10.47 25.6K Aug 5, 2022 Direct F1
transaction DVAX Common Stock Sale -$15.3K -900 -3.51% $17.01 24.7K Aug 5, 2022 Direct F1, F2
transaction DVAX Common Stock Options Exercise $46.6K +4.45K +18.01% $10.47 29.2K Aug 8, 2022 Direct F1
transaction DVAX Common Stock Sale -$76.4K -4.45K -15.26% $17.16 24.7K Aug 8, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DVAX Stock Option (Right to Buy) Options Exercise -900 -6.57% 12.8K Aug 5, 2022 Common Stock 900 $10.47 Direct F1, F4, F5
transaction DVAX Stock Option (Right to Buy) Options Exercise -4.45K -34.78% 8.35K Aug 8, 2022 Common Stock 4.45K $10.47 Direct F1, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 15, 2021.
F2 This transaction was executed in multiple trades at prices ranging from $17.00 to $17.07; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.
F3 This transaction was executed in multiple trades at prices ranging from $17.00 to $17.43; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.
F4 This option grant will vest over three (3) years with one-third (1/3) of the shares subject to the option vesting twelve months after the grant date, and one thirty-sixth (1/36) of the shares subject to the option vesting on the last day of each month thereafter.
F5 Not applicable.